Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BPMED CO., LTD. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, GOUGH, TIFFANY MAUREEN, who is the busiest examiner for the company with 1 pending matter. The prosecution is confined to a single art unit, showing a concentrated prosecution front.
The focus on the pending office action within the art unit suggests a highly specialized patenting strategy for the company. Working with GOUGH, TIFFANY MAUREEN allows for a consistent and predictable interaction with the patent office. This streamlined approach in the Biotechnology & Pharmaceuticals area helps the company manage its intellectual property assets with optimal resource allocation.
For the practitioner, the data indicates a low-complexity environment with only 1 pending office action to address. The involvement of the examiner and the art unit means that the legal strategy can be precisely tailored to the examiner's specific requirements. This focused prosecution ensures that the matter in the Biotechnology & Pharmaceuticals field is handled with a clear and direct approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOUGH, TIFFANY MAUREEN | 1 | 31.6% | +46.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704129 | COMPOSITION COMPRISING BOTULINUM-DERIVED PEPTIDE FOR PAIN RELIEF | GOUGH, TIFFANY MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704129 | COMPOSITION COMPRISING BOTULINUM-DERIVED PEPTIDE FOR PAIN RELIEF | GOUGH, TIFFANY MAUREEN | 1651 | §102 | Non-Final OA | — | Pending | Apr 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial